

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM363012

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
UCB PHARMA, S.A.		11/18/2015	CORPORATION: BELGIUM
RECEIVING PARTY DATA			
Name:	UCB Biopharma SPRL		
Street Address:	Allée de la Recherche, 60		
City:	B-1070, Brussels		
State/Country:	BELGIUM		
Entity Type:	Société Privée à Responsabilité Limitée: BELGIUM		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	2454519	KEPPRA	
Registration Number:	2726258	KEPPRA LEVETIRACETAM	
CORRESPONDENCE DATA			
Fax Number:	2027218250		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	202-721-8227		
Email:	cemonid@wenderoth.com		
Correspondent Name:	Rebecca Gan		
Address Line 1:	1030 15th Street, N.W., Suite 400 East		
Address Line 2:	Wenderoth		
Address Line 4:	Washington, D.C. 20005		
ATTORNEY DOCKET NUMBER:	TM99-062		
DOMESTIC REPRESENTATIVE			
Name:	Rebecca Gan		
Address Line 1:	1030 15th Street, N.W., Suite 400 East		
Address Line 2:	Wenderoth		
Address Line 4:	Washington, D.C. 20005		
NAME OF SUBMITTER:	Rebecca Gan		
SIGNATURE:	/rgan/		

OP \$65.00 2454519

DATE SIGNED:	11/19/2015
---------------------	------------

Total Attachments: 2

source=2015 11 19 - EXECUTED TRADEMARK ASSIGNMENT - KEPPRA - KEPPRA (stylized & colours) - US#page1.tif

source=2015 11 19 - EXECUTED TRADEMARK ASSIGNMENT - KEPPRA - KEPPRA (stylized & colours) - US#page2.tif

TRADEMARK ASSIGNMENT

WHEREAS, UCB Pharma, S.A. (hereinafter "Assignor"), a corporation of Belgium, having its principal place of business at Allée de la Recherche, 60 B-1070, Brussels BELGIUM, owns the mark and registration thereof for U.S. Trademark Registration No. 3,665,183 for the mark KEPPRA XR for "Pharmaceutical preparations acting on the central nervous system" in Class 5 (hereinafter "the Mark"), as depicted in **Schedule A**; and


WHEREAS, UCB Biopharma SPRL (hereinafter "Assignee"), a société privée à responsabilité limitée of BELGIUM, having its principal place of business at Allée de la Recherche, 60 B-1070, Brussels, BELGIUM, desires to acquire all right, title and interest in the Mark and the registration thereof; and

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign to Assignee all right, title and interest in and to the Mark, including all common law rights, registrations or applications therefor, all rights of Assignor to petition, sue or otherwise seek and recover damages, profits and any other remedy (monetary, injunctive, declaratory or other), in the United States and anywhere, for any past, present or future infringement, conversion or misappropriation of, or other injury, offense, violation, breach of duty or wrong relating to the Mark, together with the goodwill of the Mark and the goodwill of the business associated with the Mark, effective as of the date of execution.

IN WITNESS WHEREOF, Assignor executed this Assignment this 18th day of November, 2015.

UCB Pharma, S.A.

18 NOV. 2015



Date

Signature

Anna RICHIO

Name

Proxy & Legal Representative

Title

SCHEDULE A

<u>MARK</u>	<u>U.S. TRADEMARK REGISTRATION NUMBER</u>	<u>REGISTRATION DATE</u>	<u>GOODS/SERVICES</u>
KEPPRA	2454519	May 29, 2001	Pharmaceutical preparations for the treatment of central nervous system diseases in Class 5
KEPPRA (stylized & colours)	2726258	June 17, 2003	Pharmaceutical preparations for the treatment of central nervous system diseases in Class 5